Fulcrum Therapeutics (FULC) News Today $3.82 +0.15 (+4.09%) (As of 10/4/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 Time Period Brokerages Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) PT at $9.33October 4 at 1:37 AM | americanbankingnews.comPetri Dish: IPO-bound drugmaker strikes BioMarin deal, plus other biotech newsOctober 3 at 7:39 AM | bizjournals.comHealthy Returns: Pfizer pulls sickle cell disease drug from markets – here’s why it mattersOctober 1, 2024 | msn.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Recommendation of "Hold" by AnalystsFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has earned an average rating of "Hold" from the ten research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buyOctober 1, 2024 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Up 41.4% in SeptemberSeptember 29, 2024 | americanbankingnews.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Sees Significant Growth in Short InterestFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) was the target of a large growth in short interest during the month of September. As of September 15th, there was short interest totalling 11,400,000 shares, a growth of 41.4% from the August 31st total of 8,060,000 shares. Based on an average trading volume of 1,680,000 shares, the days-to-cover ratio is presently 6.8 days.September 29, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Stock, Insider Trading ActivitySeptember 27, 2024 | benzinga.comFulcrum Therapeutics Shares Rise 26% on Sickle Cell Disease Market OpportunitySeptember 27, 2024 | marketwatch.comFulcrum Therapeutics swings up 17% on Pfizer sickle cell drug setbackSeptember 27, 2024 | msn.comFULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!September 25, 2024 | globenewswire.comFulcrum Therapeutics to Cut 29 Jobs Amid Reprioritization of R&DSeptember 24, 2024 | marketwatch.comFULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!September 23, 2024 | prnewswire.com186,727 Shares in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Bought by Bank of New York Mellon CorpBank of New York Mellon Corp bought a new stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 186,727 shares of the compaSeptember 21, 2024 | marketbeat.comFULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!September 19, 2024 | globenewswire.comBrokers Issue Forecasts for Fulcrum Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:FULC)Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Stock analysts at Leerink Partnrs lifted their FY2024 earnings estimates for Fulcrum Therapeutics in a research report issued to clients and investors on Thursday, September 12th. Leerink Partnrs analyst J. Schwartz now anticipates that theSeptember 16, 2024 | marketbeat.comFULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!September 15, 2024 | prnewswire.comRBC Capital Downgrades Fulcrum Therapeutics (FULC)September 15, 2024 | msn.comBuy Rating on Fulcrum’s Losmapimod: Navigating FSHD Treatment Potential Despite Phase 2 ChallengesSeptember 13, 2024 | markets.businessinsider.comStifel Downgrades Fulcrum Therapeutics (FULC)September 13, 2024 | msn.comB of A Securities Downgrades Fulcrum Therapeutics (FULC)September 13, 2024 | msn.comHold Rating on Fulcrum Therapeutics Amid Phase 3 Drug Failure and Pivot to Sickle Cell Disease CandidateSeptember 13, 2024 | markets.businessinsider.comBreaking Down Fulcrum Therapeutics: 7 Analysts Share Their ViewsSeptember 13, 2024 | benzinga.comFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 13, 2024 | globenewswire.comFULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!September 13, 2024 | globenewswire.comFulcrum Therapeutics (NASDAQ:FULC) Downgraded to Neutral at HC WainwrightHC Wainwright lowered Fulcrum Therapeutics from a "buy" rating to a "neutral" rating and decreased their target price for the company from $17.00 to $4.00 in a research report on Friday.September 13, 2024 | marketbeat.comFulcrum downgraded after setback for lead program (update)September 13, 2024 | msn.comFulcrum Therapeutics (NASDAQ:FULC) Downgraded by Royal Bank of Canada to Sector PerformRoyal Bank of Canada cut Fulcrum Therapeutics from an "outperform" rating to a "sector perform" rating and dropped their price objective for the stock from $15.00 to $4.00 in a report on Thursday.September 12, 2024 | marketbeat.comFulcrum's muscle disorder drug fails in late-stage studySeptember 12, 2024 | reuters.comFULC Investors Have Opportunity to Join Fulcrum Therapeutics, Inc. Fraud Investigation with the Schall Law FirmSeptember 12, 2024 | tmcnet.comFulcrum shares collapse as Sanofi-partnered muscular dystrophy drug fails key testSeptember 12, 2024 | finance.yahoo.comFulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal TrialSeptember 12, 2024 | finance.yahoo.comFulcrum Therapeutics IncSeptember 12, 2024 | reuters.comFulcrum stock slumps after muscle disorder drug fails in late-stage studySeptember 12, 2024 | msn.comFulcrum Therapeutics Shares Sink After Losmapimod Trial Misses EndpointSeptember 12, 2024 | marketwatch.comFulcrum crashes as GSK-partnered lead program failsSeptember 12, 2024 | msn.comFulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)September 12, 2024 | globenewswire.comB of A Securities Upgrades Fulcrum Therapeutics (FULC)September 11, 2024 | msn.comFulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle DiseaseSeptember 9, 2024 | benzinga.comFulcrum Therapeutics (NASDAQ:FULC) Shares Gap Up to $8.54Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap Up to $8.54September 9, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Upgraded to "Neutral" by Bank of AmericaBank of America raised shares of Fulcrum Therapeutics from an "underperform" rating to a "neutral" rating and raised their price objective for the company from $5.00 to $10.00 in a research note on Monday.September 9, 2024 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Buy" from AnalystsFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has been given an average rating of "Buy" by the six analysts that are presently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average twelve-month price objective amongSeptember 6, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Shares Up 5.2%Fulcrum Therapeutics (NASDAQ:FULC) Trading Up 5.2%September 4, 2024 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Sees Large Growth in Short InterestFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) was the recipient of a large growth in short interest in the month of August. As of August 15th, there was short interest totalling 8,150,000 shares, a growth of 6.1% from the July 31st total of 7,680,000 shares. Based on an average daily trading volume, of 901,700 shares, the days-to-cover ratio is presently 9.0 days.September 2, 2024 | marketbeat.comOne Fulcrum Therapeutics Insider Raised Their Stake In The Previous YearAugust 28, 2024 | finance.yahoo.com3 High-Potential Biotech Stocks Under $10August 27, 2024 | entrepreneur.comFulcrum Therapeutics to Participate in Upcoming September ConferencesAugust 27, 2024 | globenewswire.comFulcrum Therapeutics Target of Unusually Large Options Trading (NASDAQ:FULC)Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) saw some unusual options trading on Tuesday. Stock traders acquired 4,020 put options on the stock. This represents an increase of approximately 205% compared to the typical daily volume of 1,320 put options.August 27, 2024 | marketbeat.comScaling Up Without Selling Out: How Biotechs Can Preserve Culture During CommercializationAugust 27, 2024 | forbes.comFulcrum Therapeutics (NASDAQ:FULC) Stock Price Up 7%Fulcrum Therapeutics (NASDAQ:FULC) Trading Up 7%August 26, 2024 | marketbeat.comThe Petri Dish: Abata lands big pharma funds; Broad’s new partnerAugust 23, 2024 | bizjournals.com Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Email Address Next opportunity for crypto millions (Ad)The floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since they first opened to investors. Wall Street is finally embracing crypto. But most investors are missing the real goldmine… Go here to discover the crypto that's about to leave Wall Street in the dust. FULC Media Mentions By Week FULC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FULC News Sentiment▼0.250.55▲Average Medical News Sentiment FULC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FULC Articles This Week▼63▲FULC Articles Average Week Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SGMO News Today BLUE News Today KZR News Today IGMS News Today SANA News Today PAHC News Today ZYME News Today ANAB News Today MESO News Today IMNM News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FULC) was last updated on 10/6/2024 by MarketBeat.com Staff From Our PartnersHow a $200,000 Mistake Unlocked a $118 Billion Gold TreasureThe window of opportunity on this gold stock is closing fast. Once word gets out, it may be too late.Monument Traders Alliance | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHow much money are you leaving on the table from the stocks you already own?Charles Payne here, and I want to let you in on a time-tested trading method that can be used to generate cash...Unstoppable Prosperity | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | SponsoredAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulcrum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
